Medical costs associated with use of systemic therapy in adults with colorectal cancer

Journal of Managed Care Pharmacy

Volumn 19, Issue 6, 2013, Pages 461-467

  Seal, Brian S ^a   Sullivan, Sean D ^c   Ramsey, Scott ^d   Shermock, Kenneth M ^e   Ren, Jinma ^g   Kreilick, Charlie ^b   Boklage, Susan H Foltz ^b   Valluri, Satish ^f   Sarma, Syam ^h   Asche, Carl V ^g  

^a US Health Economics and Outcomes Research   (United States)

^b Bayer HealthCare Pharmaceuticals Inc   (United States)

^c UNIVERSITY OF WASHINGTON   (United States)

^d Fred Hutchinson Cancer Research Center   (United States)

^e JOHNS HOPKINS HOSPITAL   (United States)

^f UNIVERSITY OF MARYLAND   (United States)

^g UNIVERSITY OF ILLINOIS   (United States)

^h NONE

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; BEVACIZUMAB; CAPECITABINE; CETUXIMAB; FLUOROURACIL; FOLINIC ACID; IRINOTECAN; OXALIPLATIN; PANITUMUMAB;

ADULT; AGED; ARTICLE; CANCER CHEMOTHERAPY; CANCER RADIOTHERAPY; CEREBROVASCULAR DISEASE; CHRONIC KIDNEY FAILURE; CHRONIC OBSTRUCTIVE LUNG DISEASE; COLORECTAL CANCER; COMORBIDITY; CONGESTIVE HEART FAILURE; DIABETES MELLITUS; DRUG COST; FEMALE; HEALTH CARE COST; HEALTH INSURANCE; HEALTH SERVICE; HUMAN; MAJOR CLINICAL STUDY; MALE; METASTASIS; RETROSPECTIVE STUDY;

EID: 84884164010     PISSN: 10834087     EISSN: None     Source Type: Journal    
DOI: 10.18553/jmcp.2013.19.6.461     Document Type: Article

References (19)

1. Jansman FG, Postma MJ, Brouwers JR. Cost considerations in the treatment of colorectal cancer. Pharmacoeconomics. 2007;25(7):537-62.
2. Ferlay J, Shin HR, Bray F, Forman D, Mathers C, Parkin DM. Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. Int J Cancer. 2010;127(12):2893-917.
3. Tilson L, Sharp L, Usher C, et al. Cost of care for colorectal cancer in Ireland: a health care payer perspective. Eur J Health Econ. 2012;13(4):511-24.
4. Fragoulakis V, Papagiannopoulou V, Kourlaba G, Maniadakis N, Fountzilas G. Cost-minimization analysis of the treatment of patients with metastatic colorectal cancer in Greece. Clin Ther. 2012;34(10):2132-42.
5. Song X, Zhao Z, Barber B, Gregory C, Cao Z, Gao S. Cost of illness in patients with metastatic colorectal cancer. J Med Econ. 2011;14(1):1-9.
6. Ferro SA, Myer BS, Wolff DA, et al. Variation in the cost of medications for the treatment of colorectal cancer. Am J Manag Care. 2008;14(11):717-25.
7. Novoa AM, Cots F, Macia F, Castells X. [Cost of the diagnostic process in colorectal cancer]. Med Clin (Barc). 2008;130(3):116-17. [Article in Spanish]
8. Karaca-Mandic P, McCullough JS, Siddiqui MA, Van Houten H, Shah ND. Impact of new drugs and biologics on colorectal cancer treatment and costs. J Oncol Pract. 2011;7(3 Suppl):e30s-37s.
9. Tappenden P, Jones R, Paisley S, Carroll C. The cost-effectiveness of bevacizumab in the first-line treatment of metastatic colorectal cancer in England and Wales. Eur J Cancer. 2007;43(17):2487-94.
10. YCHARTS. US Health Care Inflation Rate: 3.08% for Mar 2013. 2013. Available at: http://ycharts.com/indicators/us_health_care_inflation_rate. Accessed May 9, 2013.
11. Brenner H, Bouvier AM, Foschi R, et al. Progress in colorectal cancer survival in Europe from the late 1980s to the early 21st century: the EUROCARE study. Int J Can. 2012;131(7):1649-58.
12. Gatta G, Ciccolallo L, Capocaccia R, et al. Differences in colorectal cancer survival between European and US populations: the importance of subsite and morphology. Eur J Cancer. 2003;39(15):2214-22.
13. Erlichman C. Fluorouracil and leucovorin for metastatic colorectal cancer. J Chemother. 1990;2(Suppl 1):S38-S40.
14. Buroker T, Miller A, Baker L, McKenzie M, Samson M, Vaitkevicius VK. Phase II clinical trial of ftorafur in 5-fluorouracil-refractory colorectal cancer. Cancer Treat Rep. 1977;61(8):1579-80.
15. Suissa S. Immortal time bias in pharmaco-epidemiology. Am J Epidemiol. 2008;167(4):492-99.
16. Dranitsaris G, Truter I, Lubbe MS. The development of a value based pricing index for new drugs in metastatic colorectal cancer. Eur J Cancer. 2011;47(9):1299-304.
17. Matthews BA, Anderson RC, Nattinger AB. Colorectal cancer screening behavior and health insurance status (United States). Cancer Causes Control. 2005;16(6):735-42.
18. Tas F, Keskin S. Age-specific incidence ratios of colorectal cancer (CRC) in Turkey: CRC in older people is increasing. Arch Gerontol Geriatr. 2012;55(2):279-82.
19. Wright GE, Barlow WE, Green P, Baldwin LM, Taplin SH. Differences among the elderly in the treatment costs of colorectal cancer: how important is race? Med Care. 2007;45(5):420-30.